236 Clinical Impact of Portal Vein Thrombosis Prior to Liver Transplantation : A Retrospective Cohort Study

Introduction. To identify the impact of portal vein thrombosis (PVT) and associated medical and surgical factors on outcomes post liver transplant (LT). Material and methods. Two analyses were performed. Analysis One: cohort study of 505 consecutive patients who underwent LT (Alberta) between 01/2002-12/2012. PVT was identified in 61 (14%) patients. Analysis Two: cohort study of 144 consecutive PVT patients from two sites (Alberta and London) during the same period. Cox multivariable survival analysis was used to identify independent associations with post-LT mortality. Results. In Analysis One (Alberta), PVT was not associated with post-LT mortality (log rank p = 0.99). On adjusted analysis, complete/occlusive PVT was associated with increased mortality (Hazard Ratio (HR) 8.4, p < 0.001). In Analysis Two (Alberta and London), complete/occlusive PVT was associated with increased mortality only on unadjusted analysis (HR 3.7, p = 0.02). On adjusted analysis, Hepatitis C (HR 2.1, p = 0.03) and post-LT portal vein re-occlusion (HR 3.2, p = 0.01) were independently associated with increased mortality. Conclusion: Well-selected LT patients who had PVT prior to LT had similar post-LT outcomes to non-PVT LT recipients. Subgroups of PVT patients who did worse post-LT (complete/occlusive thrombosis pre-LT, Hepatitis C or post-LT portal vein re-occlusion) warrant closer evaluation in listing and management post-LT.

[1]  S. Agarwal,et al.  Portal Vein Thrombosis Is a Risk Factor for Poor Early Outcomes After Liver Transplantation: Analysis of Risk Factors and Outcomes for Portal Vein Thrombosis in Waitlisted Patients , 2016, Transplantation.

[2]  G. Ioannou,et al.  Portal vein thrombosis is not associated with increased mortality among patients with cirrhosis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  T. Hibi,et al.  When and Why Portal Vein Thrombosis Matters in Liver Transplantation: A Critical Audit of 174 Cases , 2014, Annals of surgery.

[4]  R. Porte,et al.  Hypercoagulability as a contributor to thrombotic complications in the liver transplant recipient , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[5]  R. Moreau,et al.  Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. , 2013, Gastroenterology.

[6]  R. Porte,et al.  Management of Nonneoplastic Portal Vein Thrombosis in the Setting of Liver Transplantation: A Systematic Review , 2012, Transplantation.

[7]  E. Tsochatzis,et al.  Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis , 2012, Liver international : official journal of the International Association for the Study of the Liver.

[8]  B. Caffo,et al.  MELD Exceptions and Rates of Waiting List Outcomes , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  A. Cucchetti,et al.  Portal Vein Thrombosis and Liver Transplantation: Evolution During 10 Years of Experience at the University of Bologna , 2011, Annals of surgery.

[10]  R. Merion,et al.  Portal vein thrombosis and liver transplant survival benefit , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[11]  J. Marrero,et al.  Portal vein thrombosis and survival in patients with cirrhosis , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  World Medical Association (WMA),et al.  Declaration of Helsinki. Ethical Principles for Medical Research Involving Human Subjects , 2009, Journal of the Indian Medical Association.

[13]  A. Gasbarrini,et al.  Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. , 2009, Journal of hepatology.

[14]  M. Senzolo,et al.  Should we give thromboprophylaxis to patients with liver cirrhosis and coagulopathy? , 2009, HPB : the official journal of the International Hepato Pancreato Biliary Association.

[15]  L. Romano,et al.  Safety and Efficacy of Anticoagulation Therapy With Low Molecular Weight Heparin for Portal Vein Thrombosis in Patients With Liver Cirrhosis , 2009, Journal of clinical gastroenterology.

[16]  Douglas G Altman,et al.  Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2008, BMJ.

[17]  J. Bragg-Gresham,et al.  Characteristics Associated with Liver Graft Failure: The Concept of a Donor Risk Index , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  V. Paradis,et al.  Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation , 2005, Gut.

[19]  C. Yurdaydın,et al.  Thrombophilic gene mutations in cirrhotic patients with portal vein thrombosis , 2005, European journal of gastroenterology & hepatology.

[20]  M. Margaglione,et al.  Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. , 2004, Journal of hepatology.

[21]  O. Boillot,et al.  Eversion Thrombectomy for Portal Vein Thrombosis During Liver Transplantation , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  M. Margaglione,et al.  Portal Vein Thrombosis after Variceal Endoscopic Sclerotherapy in Cirrhotic Patients: Role of Genetic Thrombophilia , 2002, Endoscopy.

[23]  G. Klintmalm,et al.  Thrombendvenectomy for Organized Portal Vein Thrombosis at the Time of Liver Transplantation , 2002, Annals of surgery.

[24]  Portal Vein Thrombosis in Adults Undergoing Liver Transplantation: Risk Factors, Screening, Management, and Outcome , 2000 .

[25]  M. Margaglione,et al.  Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis , 2000, Hepatology.

[26]  T. Starzl,et al.  A high incidence of native portal vein thrombosis in veterans undergoing liver transplantation. , 1996, The Journal of surgical research.

[27]  E. Schiff,et al.  Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. , 2015, Gastroenterology.

[28]  M. Manns,et al.  Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. , 2015, Gastroenterology.

[29]  B. Raval,et al.  Portal vein thrombosis: imaging findings. , 1994, AJR. American journal of roentgenology.